Disease_category,Disease,Protein,Protein_definition,Method,Nb_SNP,OR[95%CI],P_value
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",CXADR,Coxsackievirus and adenovirus receptor,Inverse variance weighted,13,0.82 [0.49-1.38],0.460703777350432
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",OCLN,Occludin,Inverse variance weighted,3,0.85 [0.45-1.58],0.602936955977619
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",VAMP5,Vesicle-associated membrane protein 5,Inverse variance weighted,2,0.73 [0.18-3.02],0.667698126492359
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",PRTG,Protogenin,Inverse variance weighted,34,0.93 [0.81-1.07],0.286679847553947
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",ADGRE1,Adhesion G protein-coupled receptor E1,Inverse variance weighted,35,1.09 [0.92-1.29],0.319718529795936
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",ADGRE5,Adhesion G protein-coupled receptor E5,Inverse variance weighted,16,1.22 [0.94-1.58],0.137894198082014
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",NRP1,Neuropilin-1,Inverse variance weighted,26,1.06 [0.87-1.31],0.551507188224188
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",ENG,Endoglin,Inverse variance weighted,18,1.08 [0.86-1.35],0.528893221387939
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",IL32,Interleukin-32,Inverse variance weighted,20,1.01 [0.78-1.32],0.922829781286233
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",IGFBP7,Insulin-like growth factor-binding protein 7,Inverse variance weighted,23,1.16 [0.94-1.43],0.17833178775081
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",MUC13,Mucin-13,Inverse variance weighted,13,1.05 [0.76-1.45],0.75931888347858
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",SEZ6L2,Seizure 6-like protein 2,Inverse variance weighted,14,1.20 [0.83-1.75],0.33522106084516
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",TNFRSF11B,Tumor necrosis factor receptor superfamily member 11B,Inverse variance weighted,30,1.03 [0.76-1.39],0.848710238067677
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",ITGB2,Integrin beta-2,Inverse variance weighted,20,1.14 [0.82-1.59],0.429986824791029
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",SPINT1,Kunitz-type protease inhibitor 1,Inverse variance weighted,21,1.03 [0.81-1.32],0.79981000392608
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",PLA2G15,Phospholipase A2 group XV,Inverse variance weighted,32,0.85 [0.70-1.04],0.122282481132269
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",LGALS3BP,Galectin-3-binding protein,Inverse variance weighted,30,1.14 [0.92-1.41],0.238941303314032
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",ROBO1,Roundabout homolog 1,Inverse variance weighted,25,1.04 [0.80-1.35],0.787085237671627
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",GPRC5C,G-protein coupled receptor family C group 5 member C,Inverse variance weighted,7,1.41 [0.83-2.38],0.201663941640935
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",ENPP2,Ectonucleotide pyrophosphatase/phosphodiesterase family member 2,Inverse variance weighted,31,0.86 [0.61-1.22],0.401278385110768
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",TIMP1,Metalloproteinase inhibitor 1,Inverse variance weighted,2,1.24 [0.32-4.88],0.754069086234835
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",IGFBPL1,Insulin-like growth factor-binding protein-like 1,Inverse variance weighted,23,0.91 [0.79-1.05],0.19320129782615
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",ITGA5,Integrin alpha-5,Inverse variance weighted,19,1.42 [1.00-2.01],0.0521247246502529
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",NFASC,Neurofascin,Inverse variance weighted,19,1.18 [0.96-1.45],0.120791436120544
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",PRCP,Lysosomal Pro-X carboxypeptidase,Inverse variance weighted,33,0.87 [0.70-1.09],0.224815632034051
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",SDC1,Syndecan-1,Inverse variance weighted,14,1.06 [0.68-1.65],0.789582094673081
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",IL1R1,Interleukin-1 receptor type 1,Inverse variance weighted,22,1.08 [0.82-1.42],0.57710084697674
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",CSF1R,Macrophage colony-stimulating factor 1 receptor,Inverse variance weighted,27,1.03 [0.78-1.36],0.843718996686965
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",CD163,Scavenger receptor cysteine-rich type 1 protein M130,Inverse variance weighted,38,1.11 [0.86-1.45],0.420076436684617
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",PCDH17,Protocadherin-17,Inverse variance weighted,47,0.90 [0.78-1.04],0.143611585186517
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",ADGRG1,Adhesion G-protein coupled receptor G1,Inverse variance weighted,9,1.44 [0.80-2.59],0.226157011537393
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",ADAMTSL2,ADAMTS-like protein 2,Inverse variance weighted,9,0.76 [0.47-1.23],0.26289677286301
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",CD48,CD48 antigen,Inverse variance weighted,32,1.03 [0.89-1.18],0.729925304851333
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",COQ7,"5-demethoxyubiquinone hydroxylase, mitochondrial",Inverse variance weighted,8,0.98 [0.62-1.57],0.942256333009411
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",CD74,HLA class II histocompatibility antigen gamma chain,Inverse variance weighted,8,1.08 [0.67-1.75],0.746915055257608
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",NT5E,5'-nucleotidase,Inverse variance weighted,64,1.26 [1.12-1.43],0.000152575603642
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",GGT1,Glutathione hydrolase 1 proenzyme,Inverse variance weighted,16,1.12 [0.85-1.49],0.415785947060881
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",ICAM1,Intercellular adhesion molecule 1,Inverse variance weighted,24,1.01 [0.83-1.22],0.951092077348692
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",MSR1,Macrophage scavenger receptor types I and II,Inverse variance weighted,25,1.12 [0.83-1.51],0.457238635041612
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",APOF,Apolipoprotein F,Inverse variance weighted,12,0.91 [0.71-1.17],0.457147677873874
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",EPHA2,Ephrin type-A receptor 2,Inverse variance weighted,5,1.48 [0.69-3.20],0.316725944180016
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",CDHR2,Cadherin-related family member 2,Inverse variance weighted,16,1.60 [0.93-2.73],0.0877452133301792
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",PTS,6-pyruvoyl tetrahydrobiopterin synthase,Inverse variance weighted,4,1.08 [0.69-1.69],0.725437985547922
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",HIP1R,Huntingtin-interacting protein 1-related protein,Inverse variance weighted,2,0.57 [0.28-1.17],0.1229053312223
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",TACSTD2,Tumor-associated calcium signal transducer 2,Inverse variance weighted,36,1.12 [0.97-1.30],0.133552469869811
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",MMP7,Matrilysin,Inverse variance weighted,15,0.95 [0.76-1.19],0.655202878826721
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",COL4A1,Collagen alpha-1(IV) chain,Inverse variance weighted,31,1.08 [0.90-1.29],0.403385490059962
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",VCAM1,Vascular cell adhesion protein 1,Inverse variance weighted,11,1.19 [0.64-2.21],0.580253283670696
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",LTBP2,Latent-transforming growth factor beta-binding protein 2,Inverse variance weighted,18,0.83 [0.55-1.25],0.380287583240163
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",FSTL3,Follistatin-related protein 3,Inverse variance weighted,7,1.22 [0.65-2.29],0.541877887707487
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",TNFSF8,Tumor necrosis factor ligand superfamily member 8,Inverse variance weighted,15,1.14 [0.83-1.55],0.424517265467297
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",CEACAM1,Carcinoembryonic antigen-related cell adhesion molecule 1,Inverse variance weighted,24,0.90 [0.71-1.13],0.345684520354866
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",TNFRSF21,Tumor necrosis factor receptor superfamily member 21,Inverse variance weighted,21,1.06 [0.70-1.62],0.77951091818181
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",FCN2,Ficolin-2,Inverse variance weighted,53,1.01 [0.88-1.15],0.900955265786979
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",TGFBI,Transforming growth factor-beta-induced protein ig-h3,Inverse variance weighted,46,1.04 [0.86-1.25],0.693711717781201
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",CRIM1,Cysteine-rich motor neuron 1 protein,Inverse variance weighted,14,0.83 [0.56-1.24],0.365442072789965
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",NCR3LG1,Natural cytotoxicity triggering receptor 3 ligand 1,Inverse variance weighted,41,1.07 [0.87-1.32],0.498195065006665
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",LTBR,Tumor necrosis factor receptor superfamily member 3,Inverse variance weighted,16,0.99 [0.78-1.25],0.928216651606646
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",SRPX,Sushi repeat-containing protein SRPX,Inverse variance weighted,2,0.35 [0.03-4.85],0.433092274535429
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",PIGR,Polymeric immunoglobulin receptor,Inverse variance weighted,31,1.58 [1.11-2.24],0.010905269592157
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",GRPEL1,"GrpE protein homolog 1, mitochondrial",Inverse variance weighted,3,1.03 [0.19-5.60],0.9745518137443
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",CHI3L1,Chitinase-3-like protein 1,Inverse variance weighted,28,0.94 [0.83-1.07],0.348217742713662
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",PLXNB2,Plexin-B2,Inverse variance weighted,37,0.97 [0.88-1.08],0.628870790434691
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",ALCAM,CD166 antigen,Inverse variance weighted,11,0.81 [0.57-1.16],0.250215312911359
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",IGSF3,Immunoglobulin superfamily member 3,Inverse variance weighted,6,1.39 [0.72-2.68],0.327803122221159
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",BAIAP2,Brain-specific angiogenesis inhibitor 1-associated protein 2,Inverse variance weighted,3,0.93 [0.35-2.50],0.893392524981629
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",ADA2,Adenosine deaminase 2,Inverse variance weighted,18,1.01 [0.79-1.29],0.932671369682375
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",ENTPD2,Ectonucleoside triphosphate diphosphohydrolase 2,Inverse variance weighted,11,0.99 [0.76-1.30],0.959524835204378
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",AGXT,Serine--pyruvate aminotransferase,Inverse variance weighted,17,1.01 [0.81-1.27],0.907270011283241
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",HAVCR2,Hepatitis A virus cellular receptor 2,Inverse variance weighted,13,1.00 [0.90-1.12],0.961847372705595
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",SCARF2,Scavenger receptor class F member 2,Inverse variance weighted,18,0.85 [0.66-1.09],0.200203683834253
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",ACE2,Angiotensin-converting enzyme 2,Inverse variance weighted,11,2.02 [1.05-3.91],0.035699658647702
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",IL4R,Interleukin-4 receptor subunit alpha,Inverse variance weighted,18,0.91 [0.70-1.17],0.466254883857053
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",IL6ST,Interleukin-6 receptor subunit beta,Inverse variance weighted,10,0.93 [0.59-1.45],0.735660816755632
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",MME,Neprilysin,Inverse variance weighted,49,1.06 [0.88-1.28],0.53797439885688
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",NOTCH3,Neurogenic locus notch homolog protein 3,Inverse variance weighted,19,0.79 [0.51-1.22],0.278875535226727
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",IL18BP,Interleukin-18-binding protein,Inverse variance weighted,13,0.83 [0.49-1.43],0.506709636160157
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",ENPP7,Ectonucleotide pyrophosphatase/phosphodiesterase family member 7,Inverse variance weighted,33,1.00 [0.85-1.17],0.959619353383562
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",AREG,Amphiregulin,Inverse variance weighted,7,1.11 [0.70-1.77],0.651228962887746
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",EDA2R,Tumor necrosis factor receptor superfamily member 27,Inverse variance weighted,12,1.31 [0.64-2.69],0.455035038819558
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",FGFR2,Fibroblast growth factor receptor 2,Inverse variance weighted,13,1.44 [0.92-2.25],0.10665108294172
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",IGFBP3,Insulin-like growth factor-binding protein 3,Inverse variance weighted,41,0.94 [0.78-1.13],0.528076640756761
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",PDGFRA,Platelet-derived growth factor receptor alpha,Inverse variance weighted,24,1.00 [0.79-1.26],0.983179334222079
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",CXCL8,Interleukin-8,Inverse variance weighted,7,0.80 [0.51-1.26],0.33485855320625
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",CA9,Carbonic anhydrase 9,Inverse variance weighted,11,0.75 [0.45-1.24],0.261443103177556
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",SULT2A1,Bile salt sulfotransferase,Inverse variance weighted,8,1.28 [0.92-1.78],0.137278136796987
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",THBS2,Thrombospondin-2,Inverse variance weighted,33,0.89 [0.75-1.07],0.218589573489467
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",CDH6,Cadherin-6,Inverse variance weighted,34,0.91 [0.80-1.05],0.192589233336669
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",HGF,Hepatocyte growth factor,Inverse variance weighted,7,0.94 [0.50-1.74],0.833466382673671
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",PGF,Placenta growth factor,Inverse variance weighted,8,0.94 [0.50-1.76],0.855190859533534
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",SIGLEC10,Sialic acid-binding Ig-like lectin 10,Inverse variance weighted,22,0.94 [0.82-1.09],0.419813386210568
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",CKAP4,Cytoskeleton-associated protein 4,Inverse variance weighted,15,0.73 [0.54-0.98],0.0381677412244313
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",SPON1,Spondin-1,Inverse variance weighted,25,0.88 [0.72-1.09],0.242386660193278
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",ITGBL1,Integrin beta-like protein 1,Inverse variance weighted,27,0.81 [0.66-0.99],0.0409441181378784
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",SPON2,Spondin-2,Inverse variance weighted,8,0.95 [0.69-1.31],0.767350024983924
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",EPS8L2,Epidermal growth factor receptor kinase substrate 8-like protein 2,Inverse variance weighted,11,1.20 [0.91-1.59],0.192532047404221
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",CLSTN2,Calsyntenin-2,Inverse variance weighted,38,0.87 [0.74-1.03],0.101251636709328
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",C7,Complement component C7,Inverse variance weighted,60,1.00 [0.91-1.09],0.961712748184197
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",GDF15,Growth/differentiation factor 15,Inverse variance weighted,14,0.96 [0.59-1.57],0.879841366306723
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",SEMA7A,Semaphorin-7A,Inverse variance weighted,25,1.18 [0.75-1.86],0.466600144234889
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",IL10RB,Interleukin-10 receptor subunit beta,Inverse variance weighted,31,1.00 [0.88-1.14],0.996709584482193
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",ADGRE2,Adhesion G protein-coupled receptor E2,Inverse variance weighted,19,0.86 [0.69-1.05],0.142431188889301
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",KRT18,"Keratin, type I cytoskeletal 18",Inverse variance weighted,8,1.32 [0.80-2.18],0.272527190796931
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",BCAM,Basal cell adhesion molecule,Inverse variance weighted,34,1.17 [1.01-1.36],0.0415958347740385
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",HAVCR1,Hepatitis A virus cellular receptor 1,Inverse variance weighted,40,1.14 [0.97-1.35],0.120062708206717
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",PLAU,Urokinase-type plasminogen activator,Inverse variance weighted,27,0.94 [0.75-1.17],0.590118903693103
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",CTSD,Cathepsin D,Inverse variance weighted,24,0.89 [0.71-1.12],0.311278094562112
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",DPP10,Inactive dipeptidyl peptidase 10,Inverse variance weighted,24,1.27 [1.00-1.60],0.0505353163415786
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",SPP1,Osteopontin,Inverse variance weighted,19,1.03 [0.66-1.63],0.890770871399559
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",CD80,T-lymphocyte activation antigen CD80,Inverse variance weighted,26,0.93 [0.78-1.10],0.383748234340787
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",C1QTNF1,Complement C1q tumor necrosis factor-related protein 1,Inverse variance weighted,11,0.96 [0.82-1.12],0.605792233433323
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",BST2,Bone marrow stromal antigen 2,Inverse variance weighted,27,0.88 [0.67-1.15],0.342348301110554
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",COL5A1,Collagen alpha-1(V) chain,Inverse variance weighted,16,1.13 [0.88-1.45],0.349752782336417
Chapter II Neoplasms,"Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)",TNFSF13B,Tumor necrosis factor ligand superfamily member 13B,Inverse variance weighted,23,1.26 [0.98-1.62],0.0686806562149899
